NCT03940664

CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 75 (actual)
• Sponsor: CHU de Reims · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aims of this study were * to analyze CD160 expression in both normal and pathological eyes from human adults * to evaluate association between CD160 presence on endothelial cells from blood vessels and retinal vascular disease

Detailed description

Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina. Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged over the past decade as the first line of treatment in some neovascular diseases of the retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological effect after prolonged use and. CD160 appeared in several experimental studies as a marker of activated endothelial cells, suggesting it could represent a promising target for novel anti-angiogenic.

Conditions

• Surgical Retinal

Interventions

Type	Name	Description
OTHER	immunohistochemistry on Formalin fixed and paraffin embedded blocks

Timeline

• Start date: 2008-01-01
• Primary completion: 2017-01-01
• Completion: 2017-07-01
• First posted: 2019-05-07
• Last updated: 2019-05-07

Locations

1 site across 1 country: France